Abstract
Prostate cancer is the most common non-cutaneous cancer among men in the United States. Most will be diagnosed at an early stage, but a significant number will still develop metastatic castration resistant disease. Docetaxel has demonstrated improved quality of life and overall survival in metastatic castration-resistant prostate cancer but virtually all patients will ultimately become refractory to taxane therapy. Second-line options are limited and new effective chemotherapeutic agents or combinations are needed in this setting. This review will focus on cytotoxic compounds in clinical investigation either in combination with taxanes in the first or second-line setting and other novel compounds, such as platinums and microtubule-targeting agents that are in active clinical investigation.
Keywords: Chemotherapy, platinum, docetaxel, microtubule-targeting agents, epothilones, prostate cancer
Anti-Cancer Agents in Medicinal Chemistry
Title: Cytotoxic Compounds in the Treatment of Castration-Resistant Prostate Cancer
Volume: 9 Issue: 10
Author(s): Patrick Lee and Jeanny B. Aragon-Ching
Affiliation:
Keywords: Chemotherapy, platinum, docetaxel, microtubule-targeting agents, epothilones, prostate cancer
Abstract: Prostate cancer is the most common non-cutaneous cancer among men in the United States. Most will be diagnosed at an early stage, but a significant number will still develop metastatic castration resistant disease. Docetaxel has demonstrated improved quality of life and overall survival in metastatic castration-resistant prostate cancer but virtually all patients will ultimately become refractory to taxane therapy. Second-line options are limited and new effective chemotherapeutic agents or combinations are needed in this setting. This review will focus on cytotoxic compounds in clinical investigation either in combination with taxanes in the first or second-line setting and other novel compounds, such as platinums and microtubule-targeting agents that are in active clinical investigation.
Export Options
About this article
Cite this article as:
Lee Patrick and Aragon-Ching B. Jeanny, Cytotoxic Compounds in the Treatment of Castration-Resistant Prostate Cancer, Anti-Cancer Agents in Medicinal Chemistry 2009; 9 (10) . https://dx.doi.org/10.2174/187152009789734991
DOI https://dx.doi.org/10.2174/187152009789734991 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Flavonoids Overcome Drug Resistance to Cancer Chemotherapy by Epigenetically Modulating Multiple Mechanisms
Current Cancer Drug Targets New Paradigm for Intrinsic Function of Heat Shock Proteins as Endogenous Ligands in Inflammation and Innate Immunity
Current Molecular Medicine Platinum Formulations as Anticancer Drugs Clinical and Pre-Clinical Studies
Current Topics in Medicinal Chemistry Selective Inhibitors of Zinc-Dependent Histone Deacetylases. Therapeutic Targets Relevant to Cancer
Current Pharmaceutical Design Targeting the Renin-angiotensin System: Whats New?
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Recent Clinical Aspects of Hyperprolactinemia Induced by Antipsychotics
Reviews on Recent Clinical Trials A Review of Animal and Human Studies for Management of Benign Prostatic Hyperplasia with Natural Products: Perspective of New Pharmacological Agents
Inflammation & Allergy - Drug Targets (Discontinued) Genes of Human Longevity: An Endless Quest?
Current Vascular Pharmacology Interrelationships Among Gut Microbiota and Host: Paradigms, Role in Neurodegenerative Diseases and Future Prospects
CNS & Neurological Disorders - Drug Targets Novel Nanotechnology Approaches for Targeted Cancer Therapy
Recent Patents on Nanomedicine Aptamers: Potential Applications to Pancreatic Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry MicroRNAs in the Pathobiology of Multiple Myeloma
Current Cancer Drug Targets Do Not Say Ever Never More: The Ins and Outs of Antiangiogenic Therapies
Current Pharmaceutical Design Texaphyrins: Tumor Localizing Redox Active Expanded Porphyrins
Anti-Cancer Agents in Medicinal Chemistry Drug Discovery and Design for Complex Diseases through QSAR Computational Methods
Current Pharmaceutical Design Cancer Drug Discovery Targeting Histone Methyltransferases: An Update
Current Medicinal Chemistry Recent Patents Review on Intranasal Administration for CNS Drug Delivery
Recent Patents on Drug Delivery & Formulation Is there a Potential Immune Dysfunction with Anabolic Androgenic Steroid Use?: A Review
Mini-Reviews in Medicinal Chemistry Application of Proteome Analysis to the Assessment of Prognosis and Response Prediction in Clinical Oncology
Current Cancer Drug Targets Patented Novelties in Immunoisolation for the Treatment of Endocrine Disorders
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery